Introduction
============

Gastrointestinal (GI) stromal tumors (GISTs), the most common mesenchymal neoplasms of the GI tract, are believed to originate from the interstitial cells of Cajal regulating GI motility. GISTs can be found anywhere within the GI tract; however, the stomach accounts for at least half of them and is the most common location.[@b1-ott-9-3387] Up to 50% of patients developed tumor recurrence after initial resection for primary and localized GISTs, and median survival after recurrence was \<2 years. The kinase mutational status has been accepted as the main pathogenic event, has been presented as the peculiar molecular hallmark of GISTs, and denoted as the best predictive biomarker of tumor response to tyrosine kinase inhibitor (TKI).[@b1-ott-9-3387]--[@b4-ott-9-3387] The detection and analysis of somatic mutations from GIST tissue are the keys to understanding the genetic basis of tumor initiation, progression, therapy response, toxicity, and patient prognosis.

The *KIT* gene, the cellular homologue of the oncogene v-*KIT*, encodes a type III receptor tyrosine kinase, c-kit.[@b5-ott-9-3387],[@b6-ott-9-3387] *KIT*, a 145 kDa glycoprotein receptor of stem cell factor (SCF), is a member of the type III receptor tyrosine kinase family that contains the macrophage colony stimulating factor receptor, the Fl cytokine receptor, as well as the platelet-derived growth factor receptors-α and -β (PDGFRA and PDGFRB).[@b7-ott-9-3387] Once interactions between c-kit and SCF occur, they lead to the activation of specific intracellular signaling pathways, such as PI3K, JAK/STAT, and Shc/Ras/MAPK cascades.[@b8-ott-9-3387],[@b9-ott-9-3387] Activation of the receptor tyrosine kinase c-kit is involved in numerous diseases, including mastocytosis,[@b10-ott-9-3387] melanoma,[@b11-ott-9-3387] multiple myeloma,[@b12-ott-9-3387] and GISTs.[@b13-ott-9-3387],[@b14-ott-9-3387] The extracellular juxtamembrane domain of KIT is important for regulating receptor activation, and the differential activity of KIT splice forms is controlled by extracellular peptide insert length.[@b15-ott-9-3387] The extended A-loop region also has a role in autoactivation of mutant KIT.[@b16-ott-9-3387] A number of factors, such as interleukin-3[@b17-ott-9-3387] and the tyrosine kinase CSK,[@b18-ott-9-3387] are able to regulate KIT and its downstream signaling.

The development of human lung cells, germ cells, erythrocytes, melanocytes, mast cells, and interstitial cells of Cajal occur through Kit--SCF interaction, while dysregulation of the complex KIT signaling network is known to be correlated with malignant transformation, tumor progression, such as lung cancer, gastric cancer, leukemias, mastocytosis, as well as GISTs.[@b19-ott-9-3387]--[@b22-ott-9-3387] A number of studies have reported that c-kit dysregulation leads to tumor proliferation, development, heterogeneity, angiogenesis, survival, and resistance to anticancer therapy.[@b22-ott-9-3387]--[@b27-ott-9-3387] The activation mechanism of the most commonly occurring mutation, D816V in exon 17 of *KIT*, has been well studied, while other mutations remain fairly uncharacterized in this respect. Recently, a lipid kinase-independent key role of PI3 kinase in *KIT*/V560D-mediated oncogenic signal transduction has been reported.[@b28-ott-9-3387] Gain-of-function mutations of *KIT* or *PDGFRA* have been found in \~80%--85% of cases.[@b3-ott-9-3387],[@b29-ott-9-3387],[@b30-ott-9-3387] Numerous types of *KIT* mutations, including point mutation, insertion, deletion, and duplication, involved in exons 9, 11, 13, and 17 have been reported in GISTs;[@b31-ott-9-3387] however, controversy still exists regarding their prognostic value.[@b32-ott-9-3387] After performing primary surgery and controlling unresectable tumors, treatment with TKIs is effective in reducing GIST recurrence.[@b33-ott-9-3387] Thus, it is essential to assess the *KIT* mutation status to predict the mutation's response to TKIs and prognosis. In this study, we review the publicly available literature to summarize the data by a meta-analysis of *KIT* mutations and analyze the clinicopathological significance and prognostic values of different types of *KIT* mutations in GISTs.

Methods
=======

Search strategy
---------------

We searched PubMed, MEDLINE, and Web of Science from the earliest date up to May 2015 using the following search terms: "gastrointestinal stromal tumor" or "GIST", "KIT", and "c-KIT". In this study, we did not include *PDGFRA*-mutant GIST patients. We also screened manually the reference lists of retrieved articles for additional articles. We screened the publications by titles first, then by the abstracts. After exclusion of duplicates and nonrelevant publications from the different databases, we then evaluated the full text version for inclusion and exclusion criteria. All clinical studies except case reports were chosen. All searched data were retrieved and evaluated. The references of selected studies and authors' bibliographies were also searched for additional relevant studies.

Selection criteria
------------------

In this meta-analysis, we collected all eligible studies evaluating the relationship between *KIT* mutation and the clinicopathological significance of GISTs. We used the following inclusion criteria: 1) study design included *KIT* mutation status and the clinicopathological significance of GISTs; 2) studies that evaluated the correlation between *KIT* mutation status and prognosis in patients with GISTs. The following exclusion criteria were considered: 1) articles that showed insufficient data to calculate the odds ratio (OR); 2) case reports, letters, reviews, expert opinions, editorials, and conference abstracts; and 3) all articles involving cell lines, human xenografts, and in vitro/ex vivo studies.

Data extraction
---------------

The eligible studies were extracted by two investigators independently. Disagreements were resolved by discussions and consensus. We determined whether *KIT* mutations were detected in the primary tumor before treatment with imatinib and whether the report had sufficient available data (usually \>15 cases). We recorded the following information for each study: year of publication, first author name, number of cases, sample source, *KIT* mutation status, and other clinicopathological parameters. Data for study characteristics and clinical information were summarized and converted into table format.

Statistics analysis
-------------------

We used Review Manager 5.2 (Cochrane Collaboration, Oxford, UK) and the Stata 12.0 (Stata Corporation, College Station, TX, USA) for this analysis. Comparisons of dichotomous measures were determined by pooled estimates of ORs and their 95% confidence intervals (CIs). We used a random-effects model to pool the ORs when there was heterogeneity among studies; otherwise, a fixed-effect model was selected. The total variation among studies was estimated by *I*-square, with significance being set at *I*^2^\>50%. Heterogeneity was determined by a chi-square test, with significance being set at *P*\<0.10. *P*-value of \<0.05 was considered to be statistically significant. A sensitivity analysis, in which one study was removed at a time, was conducted to assess the result stability. We used funnel plots for detection of publication bias.

Results
=======

Identification of relevant studies
----------------------------------

Six hundred and ninety-three publications were identified by the search method described. Six hundred and sixty-five of these were excluded because they were nonoriginal articles (reviews), laboratory studies, or studies irrelevant to the current analysis. There were 28 studies identified in the final meta-analysis ([Figure 1](#f1-ott-9-3387){ref-type="fig"}).

Study characteristics
---------------------

Twenty-eight studies published from 1999 to 2014 were eligible for the analysis. A total of 4,449 GIST patients from the People's Republic of China, Korea, Taiwan, Japan, Italy, Germany, Norway, Belgium, Spain, Greece, Sweden, and the USA were enrolled. As described earlier, the database search generated 693 articles from MEDLINE, PubMed, the Web of Science, Scopus, and Embase. The other 665 publications were excluded due to lack of full text or because they were in vitro/ex vivo studies, used cell lines and human xenografts, or were irrelevant studies. The following items were collected from each study: year of publication, first author's name, countries, number of patients, tumor location, tumor size, the number of mitoses per 50 high-power fields (HPFs) in the GIST tumor section, *KIT* mutation status, treatment, and the time of follow-up. Their basic characteristics are summarized in [Table 1](#t1-ott-9-3387){ref-type="table"}.

*KIT* mutation status and clinicopathological features
------------------------------------------------------

### *KIT* mutation was not significantly associated with tumor location

To determine whether or not the *KIT* mutation could be linked to the location of tumor, we analyzed eight studies including 2,355 patients. OR was 1.00, 95% CI was in the range of 0.51--1.95, *z*=0.01, and *P*=0.99 ([Figure 2](#f2-ott-9-3387){ref-type="fig"}), indicating that the rate of *KIT* mutation was not significantly changed between GISTs in stomachs and those in small intestines.

### *KIT* mutation was significantly associated with tumor size

Considering the tumor size, OR was 1.51, 95% CI: 1.05--2.17, *z*=2.22, and *P*=0.03 ([Figure 3](#f3-ott-9-3387){ref-type="fig"}), indicating that *KIT* mutations were significantly more frequently observed in patients with larger size (\>5 cm) of GISTs than those with smaller size (\<5 cm) of GISTs.

### *KIT* mutation was significantly correlated with tumor mitosis index

To determine whether or not the *KIT* mutation could be linked to the tumor mitosis indexes (MIs), we analyzed seven studies including 899 patients. We found that the *KIT* mutation was significantly increased in patients with higher MIs (\>5/50 HPFs) of GISTs compared to patients with lower MIs (\<5/50 HPFs) of tumors. OR was 1.89, 95% CI ranged between 1.39 and 2.56, *z*=4.05, and *P*\<0.0001 ([Figure 4](#f4-ott-9-3387){ref-type="fig"}).

### *KIT* mutation was significantly correlated with tumor recurrence

*KIT* mutation-positive patients showed a significantly higher rate of recurrence compared to *KIT* mutation-negative patients. OR was 2.06, 95% CI: 1.37--3.11, *z*=3.46, and *P*=0.0005 ([Figure 5](#f5-ott-9-3387){ref-type="fig"}).

### *KIT* mutation was significantly correlated with tumor metastasis

*KIT* mutation-positive patients showed a significantly higher rate of tumor metastasis compared to *KIT* mutation-negative patients. OR was 2.77, 95% CI was 1.64--4.67, *z*=3.82, and *P*=0.0001 ([Figure 6](#f6-ott-9-3387){ref-type="fig"}).

### *KIT* mutation was significantly correlated with the overall survival of patients

*KIT* mutation-positive patients showed a worse prognosis compared to *KIT* mutation-negative patients, which was supported by the 3-year overall survival analysis. OR was 0.47, 95% CI: 0.25--0.90, *z*=2.30, and *P*=0.02 ([Figure 7](#f7-ott-9-3387){ref-type="fig"}).

### Further analysis of effects of different *KIT* mutations on patient overall survival

Finally, with respect to progression-free survival (PFS), OR was 3.60, 95% CI was 2.17--5.98, *z*=4.96, and *P*\<0.00001 ([Figure 8A](#f8-ott-9-3387){ref-type="fig"}), indicating that PFS was significantly worse in patients with *KIT* exon 9 mutations than in those with *KIT* exon 11 mutations. OR was 0.36, 95% CI 0.24--0.56, *z*=4.68, and *P*\<0.00001 ([Figure 8B](#f8-ott-9-3387){ref-type="fig"}), indicating that the 5-year PFS rate was significantly lower in patients with *KIT* exon 11 deletion than in those with other types of *KIT* exon 11 mutations. Moreover, OR was 0.19, 95% CI was 0.05--0.65, *z*=2.64, and *P*=0.008 ([Figure 8C](#f8-ott-9-3387){ref-type="fig"}), indicating that 5-year PFS was significantly worse in patients with GISTs bearing deletions involving *KIT* codon 557--558 than in those bearing other deletions of *KIT* exon 11.

Sensitivity analyses and publication bias
-----------------------------------------

A sensitivity analysis was performed by testing the result stability by removing one study at a time. The pooled ORs were not significantly changed, which confirmed the stability of our analyses. The funnel plots were largely symmetric, suggesting that there were no publication biases in terms of *KIT* mutations and clinicopathological features ([Figure 9](#f9-ott-9-3387){ref-type="fig"}).

Discussion
==========

Previous studies have shown controversial results for the prognostic value of mutational status in GIST patients, in addition to tumor size, tumor site, and mitotic count, due to the relatively small number of tested samples in each study or the limited number of analyzed studies.[@b13-ott-9-3387],[@b34-ott-9-3387]--[@b37-ott-9-3387] The discrepancy between different studies could be explained by the variations in methods, varied interpretation of the results, heterogeneous patient populations, different clinical treatments, limited number of patients in studies, but most probably different types of *KIT* mutations. In this study, we first compared the frequency of *KIT* mutations in different locations, the sizes of tumors, and different MIs. Our results demonstrated that the rate of *KIT* mutation was not significantly changed between GISTs in stomachs and those in small intestines. However, *KIT* mutations were significantly more frequently observed in patients with larger sizes (\>5 cm) of GISTs than in those with smaller sizes (\<5 cm) of GISTs. In addition, *KIT* mutation was significantly increased in patients with higher MIs (\>5/50 HPFs) of GISTs compared to patients with lower MIs (\<5/50 HPFs) of tumors. Garces-Albir et al[@b38-ott-9-3387] reported that GIST tumors \>5 cm and the presence of \>5 mitoses/50 HPFs were obviously associated with worse outcome. Tumor size and mitotic counts traditionally have been the two factors for estimation of prognosis.[@b39-ott-9-3387] A previous study has also reported that there is a direct relationship between the presence of mutation in tumor, tumor size, and mitotic count,[@b34-ott-9-3387] which is in agreement with our results. We further demonstrated by whole-gene sequencing that *KIT* mutation-positive patients showed a significantly higher rate of recurrence compared to *KIT* mutation-negative patients who did not have *KIT* gene mutations: OR was 2.06, 95% CI 1.37--3.11, *z*=3.46, and *P*=0.0005. *KIT* mutation-positive patients showed a significantly higher rate of tumor metastasis compared to *KIT* mutation-negative patients: OR was 2.77, 95% CI 1.64--4.67, *z*=3.82, and *P*=0.0001. In addition, the *KIT* mutation-positive patients showed a worse prognosis compared to the *KIT* mutation-negative patients, which was supported by the 3-year overall survival analysis: OR was 0.47, 95% CI 0.25--0.90, *z*=2.30, and *P*=0.02. Taken together, our results strongly support the hypothesis that *KIT* mutation status is another evaluable factor to estimate prognosis in GISTs, in addition to tumor size and mitotic counts. Therefore, determination of *KIT* mutations is a potential prognostic marker in GIST patients.

Mutations of the *KIT* gene in GISTs occur most frequently in *KIT* exon 11, followed by those in *KIT* exon 9; less frequently, mutations occur in exon 13 or exon 17.[@b40-ott-9-3387] We determined that the PFS of GIST patients was significantly worse in patients with *KIT* exon 9 mutations than in those with *KIT* exon 11 mutations. A few studies have shown that tumors containing deletions in the *KIT* exon 11, which most frequently involved the 5′ portion between codons 550 and 560,[@b41-ott-9-3387] are clinically more aggressive than tumors with other types of mutations. However, several studies have reported inconsistent results.[@b42-ott-9-3387]--[@b45-ott-9-3387] Our result showed that 5-year RFS rate was significantly lower in patients with *KIT* exon 11 deletion than in those with other types of *KIT* exon 11 mutations. Deletions in *KIT* exon 11 were most frequently observed in the 5′ portion between codons 550 and 560 and occurred less frequently between codons 562 and 579.[@b42-ott-9-3387],[@b43-ott-9-3387],[@b46-ott-9-3387] There was no significant difference in the rate of response to imatinib or the median PFS among patients with exon 11 deletion, point mutations, and mixed-type mutations.[@b47-ott-9-3387],[@b48-ott-9-3387] A few studies showed inconsistent results in terms of 5-year RFS in patients of GIST with codon 557--558 deletion and other deletions of *KIT* exon 11 due to the small number of patient samples.[@b42-ott-9-3387],[@b43-ott-9-3387],[@b45-ott-9-3387],[@b46-ott-9-3387] In this analysis, we showed that RFS for 5 years was significantly worse in patients with GISTs bearing deletions involving *KIT* codon 557--558 than in those bearing other deletions of *KIT* exon 11.

The GIST paradigm has been proven to be more complex than expected, due to a molecular heterogeneity within all GIST tumors and the identification of different subgroups characterized by a peculiar genotype--phenotype.[@b49-ott-9-3387] With the application of high-throughput technologies of gene mutation analysis, a wide spectrum of other genomic alterations can be identified in GIST tumors. The biological role and clinical significance of most of these additional events, such as *PDGFRA* gain-of-function mutations, in GIST pathogenesis and development remain undefined. Besides the importance of *KIT* mutation status in predicting imatinib sensitivity and prognosis, the acquisition of secondary mutations in *KIT* represents the most frequent mechanism of imatinib resistance and worse prognosis in GIST patients. However, most of the studies till date have only reported one case or a few cases of secondary *KIT* mutations or have insufficient follow-up data;[@b50-ott-9-3387]--[@b53-ott-9-3387] we are hence not able to perform a meta-analysis to compare the significance of primary and secondary *KIT* mutations in GIST patients. Acquired secondary *KIT* mutations are the major cause of secondary imatinib resistance and are important in the development of new therapeutic strategies in advanced GISTs.[@b54-ott-9-3387] The predictive value of secondary *KIT* mutations in GIST patients needs further study. Therefore, additional research in the future, especially larger prospective studies, will be needed to evaluate the correlation between mutation status of *KIT* and/or other genes and their clinicopathological significance in GIST patients.

Conclusion
==========

In summary, through the analysis of 4,449 patients from 28 eligible studies, we have shown that *KIT* mutation status is closely correlated with size of tumors and MIs, but not with tumor location. *KIT* mutation has also been observed to be significantly correlated with tumor recurrence, metastasis, and the overall survival of patients. GIST patients with *KIT* exon 9 mutations have higher risk of progression than those with exon 11 mutations, and 5-year RFS rate was significantly higher in patients with *KIT* exon 11 deletion than in those with other types of *KIT* exon 11 mutations. In addition, RFS for 5 years was significantly worse in patients with GISTs bearing deletions involving *KIT* codons 557--558 than in those bearing other deletions of *KIT* exon 11. Our results strongly support the hypothesis that *KIT* mutation status is another evaluable factor to estimate prognosis in GISTs, besides tumor size and mitotic counts. Therefore, determination of differential *KIT* mutation status is a potential prognostic marker for GIST patients.
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![Forest plot for *KIT* mutation status in stomachs and those in small intestines.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel odds ratio.](ott-9-3387Fig2){#f2-ott-9-3387}

![Forest plot for *KIT* mutation status in patients with larger size (\>5 cm) and those with smaller size (\<5 cm) of GISTs.\
**Abbreviations:** CI, confidence interval; GIST, gastrointestinal stromal tumor; M--H, Mantel--Haenszel odds ratio.](ott-9-3387Fig3){#f3-ott-9-3387}

![Forest plot for *KIT* mutation status in patients with higher mitosis indexes (MIs) (\>5/50 HPFs) and patients with lower MIs (\<5/50 HPFs) of tumors.\
**Abbreviations:** CI, confidence interval; HPF, high-power field; M--H, Mantel--Haenszel odds ratio.](ott-9-3387Fig4){#f4-ott-9-3387}

![Forest plot for *KIT* mutation status and tumor recurrence.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel odds ratio.](ott-9-3387Fig5){#f5-ott-9-3387}

![Forest plot for *KIT* mutation status and tumor metastasis.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel odds ratio.](ott-9-3387Fig6){#f6-ott-9-3387}

![Forest plot for *KIT* mutation status and the overall survival of patients.\
**Abbreviations:** CI, confidence interval; M--H, Mantel--Haenszel odds ratio.](ott-9-3387Fig7){#f7-ott-9-3387}

![Effects of different *KIT* mutation toward patient overall survival.\
**Notes:** (**A**) Forest plot for *KIT* mutation status in patients with *KIT* exon 9 mutations and in those with *KIT* exon 11 mutations. (**B**) Forest plot for *KIT* mutation status in patients with *KIT* exon 11 deletion and in those with other types of *KIT* exon 11 mutations. (**C**) Forest plot for *KIT* mutation status in patients with GISTs bearing deletions involving *KIT* codons 557--558 and in those bearing other deletions of *KIT* exon 11.\
**Abbreviations:** CI, confidence interval; GIST, gastrointestinal stromal tumor; M--H, Mantel--Haenszel odds ratio.](ott-9-3387Fig8){#f8-ott-9-3387}

![Funnel plot for publication bias.\
**Notes:** (**A**) *KIT* mutation of patients with GIST in stomach and small intestine. (**B**) *KIT* mutation in different sizes of GIST. (**C**) *KIT* mutation in different MIs of GISTs. (**D**) *KIT* mutation status and tumor recurrence. (**E**) *KIT* mutation status and tumor metastasis. (**F**) *KIT* mutation status and the overall survival of patients. (**G**) *KIT* mutation status in GIST patients with *KIT* exon 11 mutation and *KIT* exon 9 mutation. (**H**) *KIT* mutation status in GIST patients with *KIT* 11 exon deletion and other *KIT* 11 exon mutation. (**I**): *KIT* mutation status in GIST patients with deletion of codons 557--558 of *KIT* 11 exon and other *KIT* 11 deletions.\
**Abbreviations:** GIST, gastrointestinal stromal tumor; SE(log\[OR\]), standard error of the regular odds ratio; MI, mitosis index.](ott-9-3387Fig9){#f9-ott-9-3387}

###### 

Main characteristics of included studies

  Study                                         Country                      Study size   Follow-up (median)   Treatment
  --------------------------------------------- ---------------------------- ------------ -------------------- -----------
  Taniguchi et al[@b34-ott-9-3387]              Japan                        124          4.1 years            Surgery
  Sakurai et al[@b35-ott-9-3387]                Japan                        48           3.7 years            Surgery
  Yamamoto et al[@b36-ott-9-3387]               Japan                        27           3.6 years            Surgery
  Garces-Albir et al[@b38-ott-9-3387]           Spain                        36           64.8 mo              Surgery
  Wozniak et al[@b44-ott-9-3387]                Belgium                      427          3.8 years            Surgery
  Dematteo et al[@b45-ott-9-3387]               USA                          127          5.2 years            Surgery
  Wardelmann et al[@b46-ott-9-3387]             Germany                      55           NA                   Surgery
  Ma et al[@b55-ott-9-3387]                     People's Republic of China   68           91.3 mo              NA
  Origone et al[@b56-ott-9-3387]                Italy                        80           NA                   NA
  Lv et al[@b57-ott-9-3387]                     People's Republic of China   114          50 mo                Surgery
  Kunstlinger et al[@b58-ott-9-3387]            Germany                      1,366        NA                   NA
  Gao et al[@b59-ott-9-3387]                    People's Republic of China   50           36 mo                Imatinib
  Soreide et al[@b60-ott-9-3387]                Norway                       38           8 years              Imatinib
  Kang et al[@b61-ott-9-3387]                   Korea                        370          43.3 mo              Imatinib
  Zheng et al[@b62-ott-9-3387]                  People's Republic of China   25           3.2 years            Surgery
  Daniels et al[@b63-ott-9-3387]                Germany                      87           NA                   NA
  Kontogianni-Katsarou et al[@b64-ott-9-3387]   Greece                       30           NA                   NA
  Tzen et al[@b65-ott-9-3387]                   People's Republic of China   134          47 mo                Surgery
  Keun et al[@b66-ott-9-3387]                   Korea                        68           5.0 years            Surgery
  Imamura et al[@b67-ott-9-3387]                Japan                        95           160 mo               Surgery
  Lin et al[@b68-ott-9-3387]                    Taiwan                       25           NA                   Surgery
  Andersson et al[@b69-ott-9-3387]              Sweden                       177          6.2 years            Surgery
  Debiec-Rychter et al[@b70-ott-9-3387]         Belgium                      476          25.3 mo              Imatinib
  Yeh et al[@b71-ott-9-3387]                    People's Republic of China   64           16.1 mo              Imatinib
  Cho et al[@b72-ott-9-3387]                    Japan                        56           56.3 mo              Imatinib
  Liu et al[@b73-ott-9-3387]                    People's Republic of China   82           4.1 years            Surgery
  Martin et al[@b74-ott-9-3387]                 Spain                        162          42 mo                Surgery
  Haller et al[@b75-ott-9-3387]                 Germany                      38           2.7 years            Surgery

**Abbreviations:** mo, months; NA, not applicable.
